Rare Disease Report

Clinical Trials with Volanensorsen (ISIS-APOCIIIrx): Familial Chylomicronemia Syndrome and Partial Lypodystrophy

JUNE 12, 2015
James Radke, PhD

Paula Soteropoulos, president and chief executive officer of Akcea Therapeutics, a subsidiary of Isis Pharmaceuticals focused on delivering transformative medicines for cardiometabolic lipid disorders, talks about the phase 3 clinical studies the company is conducting to bring volanesorsen (ISIS-APOCIIIRX) to market. 

To learn more about the clinical trials, go to www.apociii.com

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.